ISSCR - Accelerating PSC-Derived Cell Therapies: Starting with the End in Mind

The complexity and heterogeneity of many diseases, particularly neurodegenerative disorders, underscore the urgent need for personalized therapeutic strategies. At the same time, growing ethical and translational limitations of animal research have accelerated the search for alternative approaches. Induced pluripotent stem cells (iPSCs) have emerged as a transformative tool to model disease and enable drug discovery directly in human-relevant systems. Several iPSC-based therapies are already advancing toward clinical application, yet realizing their full potential requires technologies capable of delivering precise, high-content functional insights.  

MaxWell Biosystems’ High-Density Microelectrode Arrays (HD-MEAs), including the MaxOne and MaxTwo platforms, provide a powerful, non-invasive approach to capture high-resolution electrophysiological data from iPSC-derived neuronal networks. These platforms enable researchers to assess neural activity and maturation with exceptional detail and reproducibility.  

In this Innovation Showcase, we highlight how HD-MEAs can provide essential functional readouts to accelerate the translation of iPSC-derived models toward therapies suitable for preclinical evaluation.

‍